EUVIMEDEUVIMED entdecken
Crossref

Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology

Vinal V Lakhani, Grant Generaux, Brett A Howell, Diane M Longo, Paul B Watkins

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.3004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Vinal V Lakhani und 4 weiteren Autor:innen. Beteiligte Einrichtung: DILIsym Services Inc., A Simulations-Plus Company, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Valproic Acid, Cannabidiol, Chemical and Drug Induced Liver Injury, Anticonvulsants. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical trials of cannabidiol (CBD) for the treatment of seizures in patients with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, elevations in serum alanine aminotransferase (ALT) > 3× the upper limit of normal were observed in some patents, but the incidence was much greater in patients who were receiving treatment with valproate (VPA) before starting CBD. To explore potential mechanisms underlying this interaction, we used DILIsym, a quantitative systems toxicology model, to predict ALT elevations in a simulated human population treated with CBD alone, VPA alone, and when CBD dosing was starting during treatment with VPA. We gathered in vitro data assessing the potential for CBD, the two major CBD metabolites, and VPA to cause hepatotoxicity via inhibition of bile acid transporters, mitochondrial dysfunction, and production of reactive oxygen species (ROS). Physiologically‐based pharmacokinetic models for CBD and VPA were used to predict liver exposure. DILIsym simulations predicted dose‐dependent ALT elevations from CBD treatment and this was predominantly driven by ROS production from the parent molecule. DILIsym also predicted VPA treatment to cause ALT elevations which were transient when mitochondrial biogenesis was incorporated into the model. Contrary to the clinical experience, simulation of 2 weeks treatment with VPA prior to introduction of CBD treatment did not predict an increase of the incidence of ALT elevations relative to CBD treatment alone. We conclude that the marked increased incidence of CBD‐associated ALT elevations in patients already receiving VPA is unlikely to involve the three major mechanisms of direct hepatotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Valproic AcidCannabidiolChemical and Drug Induced Liver InjuryAnticonvulsantsLiverHumansAlanine TransaminaseDose-Response Relationship, DrugModels, BiologicalReactive Oxygen SpeciesComputer SimulationDrug InteractionsDrug Therapy, Combination

Substanzen

Valproic AcidCannabidiolAnticonvulsantsAlanine TransaminaseReactive Oxygen Species

Autor:innen und Institutionen

  • DILIsym Services Inc., A Simulations-Plus Company, Durham, North Carolina, USA.
  • UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • UNC Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Zitieren

APA

Lakhani, V. V., Generaux, G., Howell, B. A., Longo, D. M., & Watkins, P. B. (2023). Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3004

Vancouver

Lakhani VV, Generaux G, Howell BA, Longo DM, Watkins PB. Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3004

BibTeX
@article{Lakhani2023,
  author = {Lakhani, Vinal V and Generaux, Grant and Howell, Brett A and Longo, Diane M and Watkins, Paul B},
  title = {Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.3004}
}
Kostenlos starten →